Arvinas, Inc. (ARVN) Stock

Arvinas, Inc. (ARVN) is a Healthcare stock trading at $7.66 (as of 2026-06-18), with a market capitalization of $496.81M and a trailing P/E of -2.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Arvinas, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies designed to degrade disease-causing proteins, including PROTAC-based candidates such as Bavdegalutamide for metastatic castration-resistant prostate cancer and ARV-471 for metastatic ER-positive/HER2-negative breast cancer. It also develops ARV-766 for men with mCRPC and conducts programs in collaboration with major pharmaceutical partners.

Valuation — source: SEC EDGAR (first-party)
Price	$7.66
Market Cap	$496.81M
P/E Ratio	-2.4
EV / EBITDA	-1.6
Price / Book	1.28
Price / Sales	5.54
DCF Value (model)	$-71.16
DCF Upside vs Price	-1029.0%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$262.60M
Net Margin	-30.8%
Return on Equity	-57.2%
Debt / Equity	0.00
Current Ratio	5.44
Revenue Growth (YoY)	-91.7%
EPS Growth (YoY)	-178.9%
FCF Growth (YoY)	-21.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	-1.36 (distress)

Valuation vs Sector & Industry
Stock P/E	-2.4
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-111.5%
vs Industry	-114.0%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($85.74M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Randy Teel
Employees	430
Country	US
IPO Date	2018-09-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.